SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings (BREA) is trending due to news of a $300M private placement to fund a Solana digital asset treasury, leading to a rebrand as Solmate. Community members are actively discussing the potential for a significant price increase, drawing comparisons to other high-flying treasury plays and low float runners. The focus is on its potential within the decentralized finance space and the backing from Ark Invest and UAE investors.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to concerns around Nvidia's investment in Intel, with the community debating the potential impact on AMD's competitive position. Many believe this is a strategic move acknowledging AMD's strength, while others worry about increased competition in both the CPU and GPU markets. Despite the uncertainty, some investors view the dip as a buying opportunity, citing AMD's strong fundamentals and future growth potential.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following news of a $5 billion investment and partnership with Nvidia to develop AI and PC products, which has sparked significant community discussion around the potential impact on Intel's market position and future growth. The community is weighing the significance of this deal, analyzing potential price movements, and evaluating the long-term implications for Intel and its competitors. Some investors suggest this marks a turning point for the company, while others express skepticism about Intel's ability to execute its turnaround strategy.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending amid anticipation of potential rate cuts, which are expected to boost the fintech company's lending business and overall valuation. The community is discussing whether the stock is poised for new all-time highs and potential S&P 500 inclusion, while some traders are weighing short-term profit-taking versus long-term growth prospects.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney's stock is trending amidst discussions around political polarization and its impact on the company, particularly concerning content choices and perceived bias. Community members are debating the company's direction and whether recent decisions will affect subscription rates and overall profitability. Some investors see the current situation as a buying opportunity, while others express concerns about the company's long-term prospects.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards AI and high-performance computing, fueled by recent CEO comments. Community members are actively watching key resistance levels and highlighting the stock's undervaluation compared to peers like IREN and CIFR. Bullish sentiment is building, with some anticipating a short squeeze and significant upside if the company successfully executes its new strategy.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the quantum computing sector gains momentum, fueled by news of government contracts and partnerships. The community is discussing the company's technology, potential for growth, and comparisons to sector peers, along with speculation about future price targets and potential acquisitions. Some traders are expressing caution due to the high valuation compared to current revenue.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is experiencing increased interest amid discussions of a potential short squeeze, driven by its low float and high short interest. The community is weighing the potential for significant upward movement against the risks associated with the stock's volatility and ties to Chinese firms. Traders are closely monitoring key resistance levels, anticipating a breakout or pullback.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community discusses the potential impact of Panasonic's recent solid-state battery announcement, with many speculating about a possible collaboration or partnership between the two companies and Tesla. Community members are actively debating potential price targets and the possibility of a short squeeze, while also discussing the broader implications for the EV battery sector. The ongoing commentary highlights both optimism and skepticism surrounding QuantumScape's technology and future prospects.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending as the community discusses its potential to fill the gap towards $377, with some anticipating a move to $400 next month amidst positive crypto news. Bullish sentiment surrounds the stock's breakout potential and institutional narrative, while bears are eyeing overbought levels and possible retracements. Recent partnership announcements and overall cryptocurrency market momentum appear to be key factors driving the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits. 

Novo Nordisk’s U.S.-listed shares rose after-hours on Wednesday after the Danish drugmaker said its new Wegovy pill helped people lose about as much weight as the weekly shot.<a href="https://stocktwits.com/symbol/NVO">Novo’s shares</a> jumped 3.5% to $60.26 in after-hours trading on Wednesday, after closing up 1.8% at $58.20 during the regular session, marking their fourth straight day of gains.The daily pill has already been sent to U.S. regulators for approval as a long-term weight-loss treatment, with a decision expected by the end of the year. If cleared, it would be the first obesity pill of its kind, and Novo said production is already underway at its U.S. plants.In a year-long study, published in the New England Journal of Medicine, participants who took the pill lost an average of nearly 17% of their body weight. By contrast, those given a placebo lost less than 3%. More than one in three participants managed to lose a fifth of their body weight or more.Even when accounting for people who didn’t stick strictly to the treatment plan, those on the Wegovy pill still lost an average of 13.6% of their weight versus 2.2% for the placebo, with nearly a third hitting the 20% weight-loss mark.&nbsp;Novo said the pill also improved cardiovascular risk factors and patients’ ability to carry out daily activities such as walking, bending, and standing. Safety was consistent with injectable Wegovy, with gastrointestinal side effects most common.At the same time, competition is intensifying. Eli Lilly announced on Wednesday that its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">experimental oral weight-loss drug, Orforglipron,</a> was found to be superior to Novo’s oral semaglutide in a head-to-head late-stage trial involving 1,698 adults with type 2 diabetes.The trial compared 12 mg and 36 mg doses of Orforglipron with 7 mg and 14 mg doses of oral semaglutide. At 52 weeks, Orforglipron lowered blood sugar by as much as 2.2% compared to 1.4% with the highest semaglutide dose, while producing greater weight reduction.&nbsp;Nearly three times as many participants on the highest Orforglipron dose reached near-normal blood sugar&nbsp;levels versus those on the highest semaglutide dose, Lilly said.Kenneth Custer, president of Lilly Cardiometabolic Health, said the results underscored Orforglipron’s strength. “At the highest dose, Orforglipron helped nearly three times as many participants reach near-normal blood sugar versus the highest dose of oral semaglutide,” he said, adding that head-to-head trials represent the “gold standard” for comparing treatments.Novo is also pursuing a strategy of more personalized care, allowing patients to switch between pill and injection depending on response, said Ludovic Helfgott, its head of product and portfolio strategy, according to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-17/novo-aims-to-beat-lilly-with-something-for-everyone-in-obesity">report</a>.&nbsp;On Stocktwits, retail sentiment for Novo Nordisk was ‘bullish’ with ‘high’ message volume, while sentiment for Eli Lilly was ‘bearish’ with ‘normal’ message volume.While Novo Nordisk’s U.S.-listed stock has declined 31% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a>&nbsp;has lost 1% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity. 

Equity

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

Eli Lilly and Company (LLY) stated on Wednesday that its oral weight-loss drug was found to be superior to its rival Novo Nordisk’s (NVO) oral Semaglutide in a head-to-head late-stage trial.The study evaluated the safety and efficacy of Lilly’s Orforglipron in 1,698 adults with type 2 diabetes as compared to oral Semaglutide. At 52 weeks, Orforglipron met the primary as well as secondary endpoints across each dose comparison vs. oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said that in the trial, Orforglipron outperformed both doses of oral Semaglutide in reducing blood glucose levels. “At the highest dose, Orforglipron helped nearly three times as many participants reach near-normal blood sugar versus the highest dose of oral Semaglutide,” he said, while adding that head-to-head trials are a “gold standard for comparing potential treatments."The trial compared 12 mg and 36 mg of Orforglipron with 7 mg and 14 mg of oral Semaglutide. Orforglipron lowered blood glucose levels by as much as 2.2% compared to 1.4% with the highest dose of oral Semaglutide at 52 weeks. Notably, 37.1% of participants taking the highest dose of Orforglipron achieved a blood glucose level lower than 5.7% compared to 12.5% taking the highest dose of oral Semaglutide, Lilly said.Furthermore, participants taking Lilly’s drug achieved as much as a 9.2% reduction in weight from baseline, compared to 5.3% with oral Semaglutide, the company said. Orforglipron also showed clinically meaningful improvements across key cardiovascular risk factors, it added.Treatment discontinuation rates due to adverse events, however, were higher in the Orforglipron population, though the study was not powered to compare the safety and tolerability of Orforglipron and oral Semaglutide.Treatment discontinuation rates due to adverse events were 8.7% for 12 mg Orforglipron and 9.7% for 36 mg Orforglipron, as compared to 4.5% for 7 mg oral Semaglutide and 4.9% for 14 mg oral Semaglutide, Lilly said.The company expects to submit applications for Orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026. Oral Semaglutide, meanwhile, is already approved for the treatment of type 2 diabetes under the name Rybelsus.LLY stock is down by 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial

At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.

U.S. stocks appear set for a cautious opening on Wednesday as the Federal Reserve gets ready to announce its latest interest rate decision.Data from the CME FedWatch&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> indicates a 94% probability of a 25-basis-point rate cut announcement on Wednesday.While Dow Jones futures were up 0.03% at the time of writing, the S&amp;P 500 futures fell 0.07%, while the tech-heavy Nasdaq 100’s futures declined 0.1%. Futures of the Russell 2000 index were up 0.02%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was down 0.07% at the time of writing, while&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) fell 0.08% on Wednesday morning. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bullish’ territory.Asian markets ended Tuesday’s trading session on a largely negative note, with the KOSPI declining the most at 1.06%, followed by the TWSE Capitalization Weighted Stock index at 0.75%, and the Nikkei 225 index at 0.17%.The Hang Seng index surged 1.86%, while the Shanghai Composite gained 0.37%.Stocks To Watch<ul><li>Workday Inc. (WDAY): Workday shares surged 8% in Wednesday’s pre-market session after Elliott Investment Management announced a $2 billion investment in the company.</li><li>Microsoft Corp. (MSFT), Nvidia Corp. (NVDA), Alphabet Inc. (GOOG) (GOOGL): U.S. tech giants announced a $40 billion investment in the U.K. amid President Donald Trump’s visit to the nation.</li><li>StubHub Holdings Inc. (STUB): The ticket reseller raised nearly $800 million in its initial public offering (IPO). The stock is set to debut on Wednesday.</li><li>GSK Plc. (GSK), Eli Lilly and Co. (LLY): The two pharmaceutical giants announced plans to build new plants in the U.S. to mitigate the impact of tariffs partly.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/martin-shkreli-shorts-opendoor-stock/chwyrOyRdz6">‘Pharma Bro’ Martin Shkreli Shorts Opendoor Technologies, Stock Tumbles 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug peresolimab and mixed results from its obesity pill candidate orforglipron weighed on investor appetite.&nbsp;In the 72-week ATTAIN-1 study, orforglipron met its main goal of superior weight reduction over placebo across all three tested doses. Patients on the highest 36 mg dose lost an average of 27.3 pounds, or 12.4% of their body weight, compared with just 2.2 pounds, or 0.9%, on placebo. Almost six in ten people shed at least 10% of their weight, and about four in ten lost 15% or more.Among the 1,127 participants with prediabetes at enrollment, up to 91% of those on treatment achieved near-normal blood sugar levels at 72 weeks, compared with 42% on placebo. The trial also showed improvements in waist circumference, cholesterol, triglycerides, blood pressure, and inflammation markers.&nbsp;However, weight loss plateaued for most patients. Researchers noted that despite the 72-week duration, weight reduction was not greater than in the prior Phase 2 trial, possibly due to differences in trial design, including greater geographic diversity and a higher proportion of male participants.The main side effects were mild-to-moderate stomach issues such as nausea, constipation, diarrhea and vomiting, with between 5.3% and 10.3% of patients stopping treatment, compared with 2.7% on placebo. No liver safety signals were seen.Orforglipron, licensed from Chugai in 2018, is also in late-stage studies for type 2 diabetes, sleep apnea and hypertension. Lilly said more than 4,500 people are enrolled in its Phase 3 ATTAIN program and that a filing in diabetes is planned for 2026.TD Cowen Downplays Peresolimab ReactionSeparately, TD Cowen analysts said Tuesday that the market reaction to Eli Lilly’s peresolimab data “seems excessive,” noting that AnaptysBio’s rival PD-1 agonist rosnilimab has reported no malignancies in any of its trials.Lilly halted development of peresolimab, an experimental PD-1 agonist for rheumatoid arthritis, after a Phase IIb study raised safety concerns. While the drug was superior to placebo at week 12 across several key endpoints, its efficacy was not clearly differentiated from existing therapies.&nbsp;In addition, malignancies were reported in patients receiving peresolimab, including two cases in each of the 1,000 mg and 400 mg dose groups through week 12, and four more cases by week 60, compared with none in the placebo arm.&nbsp;Reports of possible major cardiovascular events also weighed on the program’s benefit–risk profile and contributed to the decision to stop development.On Stocktwits, retail sentiment for Lilly was ‘bearish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/LLY">Lilly’s stock</a> has declined 0.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Why Is Eli Lilly’s Stock Slipping Premarket?

The drugmaker’s oral GLP-1 pill orforglipron showed mixed data in a Phase 3 trial, and regulatory filing for obesity is targeted as early as next year.

GSK’s U.S.-listed shares ticked&nbsp;nearly 2% higher after-hours Tuesday after the British drugmaker said it will pour $30 billion into U.S. research and manufacturing over the next five years,&nbsp;the latest move by a major pharmaceutical company to expand domestic production under President Donald Trump’s "America first" push.The investment includes a fresh $1.2 billion package to build new labs and factories, expand drug-substance production, and roll out AI and digital technology across five existing plants. GSK said the money will support hundreds of new high-skilled jobs alongside construction work.A centerpiece of the plan is a new biologics “flex” factory at Upper Merion, Pennsylvania, scheduled to break ground in 2026. The site will focus on medicines for respiratory illnesses such as asthma and COPD, as well as cancer. GSK is also adding new auto-injector and assembly capabilities as part of the push.“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation,” CEO Emma Walmsley said, adding that the company’s $30 billion commitment would further cement its U.S. research and supply-chain base.The move comes as other global drugmakers step up U.S. spending. Earlier Tuesday, Eli Lilly announced a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">$5 billion facility west of Richmond, Virginia,</a> that will make complex cancer and autoimmune medicines and create more than 2,400 jobs. Johnson &amp; Johnson and AstraZeneca have each pledged around $50 billion in U.S. expansion by 2030.Big Pharma’s building spree&nbsp;indicates both opportunity and pressure&nbsp;as&nbsp;several companies are still trying to patch supply-chain weaknesses exposed during the Covid-19 pandemic, while the Trump administration has threatened tariffs of up to 250% on imported medicines.&nbsp;GSK, which employs about 15,000 people in the U.S., has already broken ground on an $800 million facility in Marietta, Pennsylvania, that will double that site’s capacity. Last year, GSK got 1.7 billion packs of medicine and 400 million vaccine doses into the hands of patients. By 2030, it wants to reach 2.5 billion people worldwide.On Stocktwits, retail sentiment for GSK was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/GSK">GSK’s U.S.-listed stock</a> has risen 22.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

Eli Lilly and Company (LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility in Virginia as it seeks to expand domestic medicine production.The new facility will be located west of Richmond in Goochland County and will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune diseases, and other advanced therapies. The company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-announces-plans-build-5-billion-manufacturing-facility">said</a> that the new site will boost its domestic manufacturing of antibody-drug conjugates, a targeted therapy designed to deliver medicines directly to diseased cells.The facility is expected to be completed within the next five years, creating 2,450 high-wage manufacturing and construction jobs. This includes 650 high-paying jobs, including engineers, scientists, operations personnel, and lab technicians, in addition to 1,800 construction jobs.The company also stated that it intends to announce three additional U.S. manufacturing sites this year and to begin producing medicines at these four facilities within five years.Shares of LLY traded nearly 2% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at 'low' levels.In February, Lilly announced its plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the U.S., bringing the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.While three of the facilities will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis, and further strengthening Lilly's supply chain, the fourth will extend the company's global parenteral manufacturing network for future injectable therapies, the company had said.The facility in Virginia is the first to be announced among the four facilities.Pharma companies have been boosting U.S. investment under pressure from the Trump administration. Last month, Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">said</a> that he would initially impose small tariffs on pharma imports, which would eventually reach 250%.LLY stock is down 1% this year and approximately 18% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-says-new-obesity-treatment-achieved-11.8-percent-body-weight-reduction-in-late-stage-study/chwymJURdz1">Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside

The company also said that it intends to announce three other U.S. manufacturing sites this year. 

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LLY News

LLY Lilly(Eli) & Co